Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | DHCR24 | Q15392 | 6/20 | 0.51 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 6/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883833 | 1.00 | MEN1 (0.68) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL13077330 | 1.00 | MEN1 (0.68) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL12869820 | 1.00 | MEN1 (0.68) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL7797018 | 1.00 | MEN1 (0.68) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL12884155 | 1.00 | MEN1 (0.68) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL1032902 | 1.00 | MEN1 (0.68) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL12869828 | 0.91 | CYP3A4 (0.60) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL12869769 | 0.91 | CYP3A4 (0.60) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL12869841 | 0.91 | CYP3A4 (0.60) | MEN1KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL12869768 | 0.91 | CYP3A4 (0.60) | MEN1KMT2AUSP2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219173-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-09-20 | — | — | US | disclosed |
| US-20070219173-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219173-A1 | LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF | NR1H2, NR4A1, NR0B1 | MEN1 4512/4885KMT2A 2834/4885USP2 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.